Oppenheimer Asset Management Inc. Has $2.09 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Oppenheimer Asset Management Inc. boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 12.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,146 shares of the company’s stock after purchasing an additional 1,725 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Neurocrine Biosciences were worth $2,085,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Norges Bank acquired a new position in shares of Neurocrine Biosciences during the fourth quarter valued at about $35,731,000. The Manufacturers Life Insurance Company lifted its stake in Neurocrine Biosciences by 18.3% in the 4th quarter. The Manufacturers Life Insurance Company now owns 116,955 shares of the company’s stock worth $15,410,000 after purchasing an additional 18,070 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Neurocrine Biosciences by 3.5% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 252,565 shares of the company’s stock valued at $34,834,000 after purchasing an additional 8,630 shares during the period. Vanguard Group Inc. grew its position in shares of Neurocrine Biosciences by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 9,710,328 shares of the company’s stock valued at $1,279,433,000 after purchasing an additional 150,485 shares in the last quarter. Finally, Perceptive Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 70.1% in the fourth quarter. Perceptive Advisors LLC now owns 270,794 shares of the company’s stock worth $35,680,000 after purchasing an additional 111,552 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Up 0.0 %

NASDAQ:NBIX opened at $122.31 on Wednesday. The firm has a market capitalization of $12.31 billion, a P/E ratio of 33.69 and a beta of 0.37. The company has a fifty day moving average of $140.13 and a 200 day moving average of $138.50. Neurocrine Biosciences, Inc. has a 52 week low of $103.63 and a 52 week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.52). The firm had revenue of $590.20 million for the quarter, compared to the consensus estimate of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The business’s revenue was up 30.4% on a year-over-year basis. During the same period last year, the company posted $0.95 earnings per share. As a group, analysts anticipate that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current year.

Insiders Place Their Bets

In other news, Director William H. Rastetter sold 14,250 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the transaction, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director William H. Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the sale, the director now owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matt Abernethy sold 14,100 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.38, for a total transaction of $2,120,358.00. Following the completion of the transaction, the chief financial officer now directly owns 31,528 shares of the company’s stock, valued at $4,741,180.64. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,798 shares of company stock worth $10,676,096. 4.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. BMO Capital Markets dropped their price objective on Neurocrine Biosciences from $142.00 to $128.00 and set a “market perform” rating for the company in a research note on Thursday, August 29th. HC Wainwright reissued a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Barclays lowered their target price on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Jefferies Financial Group increased their price target on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $162.20.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.